Proteomic Profiling Identifies Specific Leukemic Stem Cell-Associated Protein Expression Patterns in Pediatric AML...

Area of Science:

• Proteomics
• Pediatric Oncology
• Hematology

Background:

• Novel therapeutic strategies are needed for pediatric acute myeloid leukemia (AML).
• Differences between leukemic and normal stem cells may offer therapeutic targets.
• Understanding proteomic variations is crucial for developing targeted treatments.

Purpose of the Study:

• To compare the proteomes of pediatric acute myeloid leukemia stem cells (AML-SCs) and blasts with healthy hematopoietic stem cells (HSCs).
• To identify differentially expressed proteins that could serve as biomarkers for pediatric AML.
• To explore potential therapeutic targets based on proteomic differences.

Main Methods:

• Mass spectrometry was used to analyze protein expression.
• Proteomes of AML-SCs and CLEC12A+ blasts from pediatric AML patients were compared to HSCs and hematopoietic progenitor cells from healthy controls.
• Differential protein expression analysis was performed.

Main Results:

• 456 shared proteins were identified in both leukemic and control samples.
• AML-SCs and leukemic blasts showed distinct protein expression profiles, dissimilar to healthy cells.
• Thirty-four proteins were differentially expressed between AML-SCs and HSCs, with notable upregulation of HSPE1, SRSF1, and NUP210.
• Downregulation of EIF2 signaling suggested protein synthesis perturbations.
• NUP210 and calreticulin were upregulated in CLEC12A+ blasts compared to HSCs.

Conclusions:

• Significant proteomic differences exist between pediatric AML stem cells and healthy HSCs.
• These findings support the exploration of AML-SC-specific biomarkers for novel pediatric AML therapies.
• Identified protein expression variations offer potential targets for future therapeutic development.